io. 23347

STATES PATENT AND TRADEN IN THE UNIT

Applicar\*

BIGHAM, Eric Cleveland et al.

JC13 Res'd PCT/PTO 2 3 OCT 2001

International Application No.:

PCT/EP00/03848

Group Art Unit:

International Filing Date: 28 APRIL 2000

Examiner:

For:

IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

Box PCT/EO/DO/US, Assistant Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[ ] [X] <i>I</i>	Copies of the references are enclosed.  Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d))  A copy of the International Search Report which issued on International Application  No. PCT/EP00/03848 is submitted herewith. All of the publications cited in the International Search  Report are listed on the attached form PTO-1449 and Applicants understand that copies have been
	5	supplied to the U.S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
B.		The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.
	[	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[	] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

[]	Applicant hereby certifies that each item of information contained in this Information Disclosur Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
[]	The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No. 07-1392.

[X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Robert H. Brink

Attorney of Record

Registration No. 36,094

Dated: 22 October 2001

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-3323 Facsimile: (919) 483-7988

## STATES PATENT AND TRADEMARK OFFICE IN THE UNIT

JC13 Rec'd PCT/PTO 2 3 OCT 2001

Applicant:

BIGHAM, Eric Cleveland et al.

International Application No.:

PCT/EP00/03848

Group Art Unit:

International Filing Date: 28 APRIL 2000

Examiner:

For:

IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

Box PCT/EO/DO/US, Assistant Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

j		Copi A co No.	les of the references are enclosed. les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the references were submitted in parent application Serial No (37 CFR 1.98(d)) les of the reference were submitted in parent application Serial No (37 CFR 1.98(d)) les of the reference were submitted in parent application Serial No (37 CFR 1.98(d)) les of the reference were submitted in pa
A.	[X]		The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []		The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	wh	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but <b>before</b> the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, iichever occurs first.
		[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
		[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
C.	[	]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.



In accordance with the requi Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign [] application not more than three months prior to the filing of this statement.

Applicant hereby petitions for the consideration of the accompanying Information Disclosure [] Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith. []

[X] Please charge any required fees to Deposit Account No. 07-1392.

[X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Robert H. Brink

Attorney of Record

Registration No. 36,094

Dated: 22 October 2001

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-3323 Facsimile: (919) 483-7988

JE13 Rec'd PCT/PTO 23 OCT 2001 INT'L APPLICATION ATTORNEY DO FORM PTO-1449 NO. NO. INFORMATION DISCLOSURE EMENT PCT/EP00/03848 PU3650USw **APPLICANT** BIGHAM et al. GROUP INT'L FILING DATE 28 April 2000 U.S. PATENT DOCUMENTS Filing Date **Subclass** Class Appropriate Name **Issue Date** Examiner **Patent** Initials Number Aug 21, 1973 Brown et al. 3,754,002 AA Huff et al. Mar 19, 1985 4,506,074 AB Continue on page FOREIGN PATENT DOCUMENTS Translation Yes | No Publication Document **Subclass** Class **Country** Date Number PCT 30 Dec 1998 EP 0 887 346 BA Continue on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Saari, Walfred S., J. Med. Chem., (1983), 26, 1769-72

EXAMINER Continue on page \_\_\_\_ DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.